Immunofluorescence Analysis of Estrogen Receptors Alpha Expression in Non-Small Cell Lung Cancer Tissue

IF 0.7 Q4 CHEMISTRY, MULTIDISCIPLINARY

Moscow University Chemistry Bulletin Pub Date : 2024-07-11 DOI:10.3103/S0027131424700159

T. A. Bogush, A. A. Basharina, I. P. Romanov, A. N. Grishanina, E. A. Bogush, A. M. Scherbakov, A. B. Ravcheeva, A. Lee, V. S. Kosorukov

{"title":"Immunofluorescence Analysis of Estrogen Receptors Alpha Expression in Non-Small Cell Lung Cancer Tissue","authors":"T. A. Bogush, A. A. Basharina, I. P. Romanov, A. N. Grishanina, E. A. Bogush, A. M. Scherbakov, A. B. Ravcheeva, A. Lee, V. S. Kosorukov","doi":"10.3103/S0027131424700159","DOIUrl":null,"url":null,"abstract":"A quantitative assessment of the expression of estrogen receptors alpha (ERα) is carried out in 115 samples of non-small cell lung cancer (NSCLC) by an immunofluorescent assay and flow cytometry. It is shown that a high level of ERα of ≥20% predicts a higher aggressiveness of NSCLC than at a low level of <20%: median survival based on a follow-up period of 78 months increases by 1.5 times; the risk of death is reduced by a factor of almost 2.0 (p = 0.04). The time to death increases on average by 18 months in about 20% of patients with a low ERα expression. The results validate the informative value of the immunofluorescence analysis and flow cytometry for quantifying the ERα expression and substantiate the prospects of antiestrogen therapy as a new option for NSCLC treatment, in particular, by analogy with breast cancer—in a long-term adjuvant therapy in ERα+ NSCLC patients.","PeriodicalId":709,"journal":{"name":"Moscow University Chemistry Bulletin","volume":"79 3","pages":"182 - 188"},"PeriodicalIF":0.7000,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Moscow University Chemistry Bulletin","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.3103/S0027131424700159","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

A quantitative assessment of the expression of estrogen receptors alpha (ERα) is carried out in 115 samples of non-small cell lung cancer (NSCLC) by an immunofluorescent assay and flow cytometry. It is shown that a high level of ERα of ≥20% predicts a higher aggressiveness of NSCLC than at a low level of <20%: median survival based on a follow-up period of 78 months increases by 1.5 times; the risk of death is reduced by a factor of almost 2.0 (p = 0.04). The time to death increases on average by 18 months in about 20% of patients with a low ERα expression. The results validate the informative value of the immunofluorescence analysis and flow cytometry for quantifying the ERα expression and substantiate the prospects of antiestrogen therapy as a new option for NSCLC treatment, in particular, by analogy with breast cancer—in a long-term adjuvant therapy in ERα⁺ NSCLC patients.

Abstract Image

查看原文本刊更多论文

非小细胞肺癌组织中雌激素受体 Alpha 表达的免疫荧光分析

摘要通过免疫荧光测定法和流式细胞术，对115份非小细胞肺癌（NSCLC）样本中雌激素受体α（ERα）的表达进行了定量评估。结果表明，ERα含量≥20%时，NSCLC的侵袭性要高于ERα含量≥20%时：以78个月的随访期为基础，中位生存期增加了1.5倍；死亡风险降低了近2.0倍（p = 0.04）。约 20% 的 ERα 低表达患者的死亡时间平均延长了 18 个月。这些结果验证了免疫荧光分析和流式细胞术在量化ERα表达方面的信息价值，并证实了抗雌激素疗法作为NSCLC治疗新选择的前景，特别是通过与乳腺癌进行类比，对ERα+ NSCLC患者进行长期辅助治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Moscow University Chemistry Bulletin CHEMISTRY, MULTIDISCIPLINARY-

CiteScore

1.30

自引率

14.30%

发文量

期刊介绍： Moscow University Chemistry Bulletin is a journal that publishes review articles, original research articles, and short communications on various areas of basic and applied research in chemistry, including medical chemistry and pharmacology.